Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | PHASE1 | NOT YET_RECRUITING | 18 | — | — | Jun 15, 2026 | Jan 15, 2030 | Mar 27, 2026 | - | — |
Determine the MTD by assessing the incidence of dose limiting toxicities (DLTs) of GB-5267
Evaluated using the Clopper-Pearson method
| Arm | Type | Description |
|---|---|---|
| IV Only | EXPERIMENTAL | Patients receive IV only infusion of GB-5267 cells |
| Dose Expansion with Combined IV and IP Infusion | EXPERIMENTAL | A combined administration of both IV and IP infusions. |
| Name | Type | Description |
|---|---|---|
| GB-5267 - IV only | BIOLOGICAL | IV infusion |
| GB-5267 -Combined IV and IP Infusion | BIOLOGICAL | IV and IP Infusion |
Inclusion Criteria: * At least 18 years of age * Patients must have epithelial ovarian, peritoneal, or fallopian tube cancer that is confirmed by histology or cytology, with a histopathological diagnosis of serous, clear cell, endometrioid, mucinous carcinoma, or carcinosarcoma. * Must have platinu...